Navigation Links
Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
Date:11/18/2013

s. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for us to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and we expect similar variability in the future. We develop product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as we may have believed at the time of entering into such relationship. Also, we or others could identify safety, side effects or manufacturing problems with our products after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims.  If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. We depend on third parties for a significant portion of our manufacturing capacity for the supply of certain of our current and future products and limits on supply may constrain sales of certain of our current products and product candidate development.

In addition, sales of our products are affected by the reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment as well as U.S. legislation affecting pharmaceutical pricing and reimbursement. Government and others' regulations and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed pro
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
(Date:12/24/2014)... 2014  Vermillion, Inc. (Nasdaq:   VRML), a bio-analytical ... that the Company closed its previously announced private ... Jack W. Schuler , Birchview Fund LLC and ... before offering expenses.  The proceeds will be used ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
(Date:12/24/2014)... On Friday, December 19, 2014, President ... Continuing Resolution Appropriations Act of 2015, which for the ... funding through the Congressionally Directed Medical Research Programs (CDMRP) ... Association (HA), working in conjunction with its allies on ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... , May 10 /PRNewswire-Asia-FirstCall/ -- BMP Sunstone,Corporation (Nasdaq: BJGP ... quarter ended March 31, 2010 . , ... David Gao , Chief ... transition at Sunstone. We replaced senior,managers including the general manager and improved ...
... Dyadic International, Inc. (Pink Sheets: DYAI) ("Dyadic"), a ... Chief Executive Officer, Mark Emalfarb , is scheduled to ... Conference in London, England on Monday, May ... ( 6:05 a.m. EDT ). Mr. Emalfarb will discuss how ...
... SAN DIEGO and OTTAWA , May 10 ... of Tom Novak , Ph.D., as vice president of ... than 15 years of experience working with large pharmaceutical companies, ... exploratory research and drug discovery efforts.  Dr. Novak will be ...
Cached Biology Technology:BMP Sunstone Reports First Quarter 2010 Financial Results 2BMP Sunstone Reports First Quarter 2010 Financial Results 3BMP Sunstone Reports First Quarter 2010 Financial Results 4BMP Sunstone Reports First Quarter 2010 Financial Results 5BMP Sunstone Reports First Quarter 2010 Financial Results 6BMP Sunstone Reports First Quarter 2010 Financial Results 7BMP Sunstone Reports First Quarter 2010 Financial Results 8BMP Sunstone Reports First Quarter 2010 Financial Results 9BMP Sunstone Reports First Quarter 2010 Financial Results 10BMP Sunstone Reports First Quarter 2010 Financial Results 11BMP Sunstone Reports First Quarter 2010 Financial Results 12Dyadic International to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference 2Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 2Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery 3
(Date:12/24/2014)...  Since its launch in December 2014, the 1U™ ... of trying to remember their usernames and passwords through replacing ... smartphones. To assist people who have struggled to remember usernames ... 1U and focuses on redefining identity, announced today that it ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... Dec. 18, 2014  23andMe, Inc., the leading personal genetics company, ... differences in genetic ancestry of individuals from across ... arrived more than four hundred years ago, the ... for peoples from different continents. This study illuminates how American ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 223andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... most promising technological research projects at University System of ... cash to help them through the most difficult phase ... With $5.1 million in federal funding, the Maryland ... research institutions and the U.S. Army Research Laboratory (ARL), ...
... one way when crammed together like sardines in a can. ... seat is empty and they have more personal space. Scientists ... involved in health and disease inside living cells. The cover ... (C&EN), ACS, weekly newsmagazine, focuses on how the study of ...
... Rensselaer Polytechnic Institute Professor Georges Belfort has ... of separations processes in biochemical engineering. Belfort, ... Engineering at Rensselaer, in recent weeks received the ... of Biological Products from the American Chemical Society ...
Cached Biology News:$5.1 million Army-Md. alliance speeds university research to market 2$5.1 million Army-Md. alliance speeds university research to market 3$5.1 million Army-Md. alliance speeds university research to market 4$5.1 million Army-Md. alliance speeds university research to market 5Rensselaer Polytechnic Institute professor Georges Belfort wins biochemical engineering award 2
... Clone/PAD: 5B15-5B-11E. Immunogen: Synthetic peptide derived ... MUC5B protein. Specificity: Specific for ... On Western blots it identifies the target ... Human (positive controls: deglycosylated secreted media from ...
Request Info...
... Immunogen KLH-conjugated, ... acids 47-66 (PAEV-GPGAVGERTPRKKEPP) of human ... 1 (BHC110/LSD1). Quality Assurance ... Stability 2 ...
Adducin beta (C-16)...
Biology Products: